News & Events
< Back to News Overview
ChemGenex Appoints Dr George Morstyn to Board of Directors
31 / 05 / 2007
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) is pleased to announce the immediate appointment of Dr George Morstyn, MB BS PhD FRACP, former Senior Vice President and Head of Development at Amgen, to its board of directors. Dr Morstyn is a highly experienced biotechnology executive with an outstanding background in pre-clinical and clinical development and regulatory affairs.
Dr Morstyn graduated from Monash University and completed a PhD with Professor Donald Metcalf at the Walter and Eliza Hall Institute. He played a significant role in the clinical development of GCSF a product widely used in cancer treatment. Dr Morstyn's substantial clinical, research and commercial experience includes training in medical oncology at the National Cancer Institute in the US, Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne (1983-1991) and a range of increasingly senior appointments at Amgen from 1991-2002.
"We are delighted to welcome Dr Morstyn to ChemGenex's board," said Greg Collier, Ph.D., Chief Executive Officer and Managing Director. "He joins us at a pivotal period as we progress Ceflatoninr through the final stages of clinical development and commercialisation in Gleevecr-resistant CML. His depth of knowledge across the oncology field, from research through to commercialization will be an invaluable asset for us."
Dr Morstyn said that he is delighted to be involved with ChemGenex as Ceflatonin progresses through late stage clinical trials. "I am very pleased to be joining the Board of ChemGenex at this exciting time.
ChemGenex has a substantial portfolio with two advanced clinical programs and strong discovery and development programs in cancer and diabetes. I look forward to contributing across the range of the company's activities."
Dr Morstyn graduated from Monash University and completed a PhD with Professor Donald Metcalf at the Walter and Eliza Hall Institute. He played a significant role in the clinical development of GCSF a product widely used in cancer treatment. Dr Morstyn's substantial clinical, research and commercial experience includes training in medical oncology at the National Cancer Institute in the US, Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne (1983-1991) and a range of increasingly senior appointments at Amgen from 1991-2002.
"We are delighted to welcome Dr Morstyn to ChemGenex's board," said Greg Collier, Ph.D., Chief Executive Officer and Managing Director. "He joins us at a pivotal period as we progress Ceflatoninr through the final stages of clinical development and commercialisation in Gleevecr-resistant CML. His depth of knowledge across the oncology field, from research through to commercialization will be an invaluable asset for us."
Dr Morstyn said that he is delighted to be involved with ChemGenex as Ceflatonin progresses through late stage clinical trials. "I am very pleased to be joining the Board of ChemGenex at this exciting time.
ChemGenex has a substantial portfolio with two advanced clinical programs and strong discovery and development programs in cancer and diabetes. I look forward to contributing across the range of the company's activities."